<![CDATA[Zanidatamab Plus Chemotherapy Extends OS in First-Line HER2+ Advanced GEA]]>
Data ReadoutpositivezanidatamabtrastuzumabPositive
AI Analysis
Summary
Updated HERIZON-GEA-01 Phase 3 data demonstrate that zanidatamab-based regimens extended overall survival compared to trastuzumab/chemotherapy in first-line HER2-positive advanced gastric/esophageal adenocarcinoma.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Zanidatamab-based regimens extended overall survival compared to trastuzumab/chemotherapy in first-line HER2-positive advanced GEA
Importance:8/10
Sentiment:
0.80
oncologygastric canceresophageal cancerHER2-positivesurvival dataPhase 3
Related Companies
Read the original article
Published by Cancer Network on September 2, 2026 3:00 PM